Pharmaceuticals and Healthcare

IMA Life to build new pharma freeze-drying equipment production site

IMA Life North America is set to establish a new $30m facility in Tonawanda, New York, US, aimed at increasing its production capabilities for pharmaceutical freeze-drying equipment.

Celltrion secures new public tenders for two biosimilars in Peru

Biopharmaceutical company Celltrion has solidified its presence in the Latin American pharmaceutical market with a series of successful public tender wins in Peru.

AcelRx Pharmaceuticals completes divestment of DSUVIA to Alora Pharmaceuticals

California-based AcelRx Pharmaceuticals has completed the divestment of DSUVIA to Alora Pharmaceuticals. 

GSK plans to spin off Consumer Healthcare unit

GlaxoSmithKline (GSK) has plans to spin off its Consumer Healthcare unit by demerging a minimum of 80% of the company’s 68% stake to its shareholders.

Xeris Pharmaceuticals to acquire Strongbridge Biopharma for $267m

US-based pharmaceutical company Xeris Pharmaceuticals has agreed to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267m.

USFDA approves Janssen’s PONVORY for treatment of multiple sclerosis

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

USFDA extends review period for AbbVie’s sNDA of upadacitinib

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.

USFDA grants FTD to efanesoctocog alfa for hemophilia A treatment

The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.

Sandoz to acquire GlaxoSmithKline’s cephalosporin antibiotics business

Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.